US Biotech Venture Capital Funding in 2021 significantly exceeds Funding in 2020

With a volume of roughly USD 33.0bn, the overall financing for US biotech companies in 2021 yet again surpassed the total funding of the previous year (USD 22.4bn). Compared to 2020, the funding volume increased significantly by 47%.

With a total of USD 9.2bn, the oncology sector received the highest funding volume, followed by central nervous system (USD 6.0bn) and infectious diseases (USD 2.2bn).

The largest deal of 2021 was the transaction of Treeline Biosciences (USD 735m), while the most active investor was Alexandria Venture Investments with 51 investments in 2021.

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here:

[a-zA-Z0-9_.-]
[a-zA-Z0-9_.-]
[a-zA-Z0-9]
[a-zA-Z0-9]